March 24, 2005Cardiovascular ResearchOpen Access

Etanercept or intravenous immunoglobulin attenuates expression of genes involved in post-myocardial infarction remodeling

View Full Paper

Ask AI

Bookmark

Why the study?

Does immunomodulatory therapy with TNFR:Fc or IVIg attenuate post-MI remodeling in rats?

Structured PICO

Does immunomodulatory therapy with TNFR:Fc or IVIg attenuate post-MI remodeling in rats?

Population

Adult male Sprague-Dawley rats subjected to myocardial infarction by left coronary artery ligation

Intervention

Recombinant soluble TNF receptor (TNFR:Fc) or intravenous immunoglobulin (IVIg)

Comparator

Vehicle

Outcome

Left and right ventricular post-MI remodeling (including RV hypertrophy, LV and arterial pressures, and gene expression)surrogate

Immunomodulatory therapy with TNFR:Fc or IVIg in the acute phase of MI attenuates cardiac remodeling and related gene expression in a rat model.

No takes yet. Share an insight, caveat, or question.

Hypothesis-generating in rat MI model; human trials required before any clinical consideration.

Gurantz et al. (2005) studied this question.

View Full Paper

Ask AI

Bookmark